(NASDAQ: XBIO) Xenetic Biosciences's forecast annual revenue growth rate of 7.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,155.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,548.38%.
Xenetic Biosciences's revenue in 2026 is $2,858,935.On average, 3 Wall Street analysts forecast XBIO's revenue for 2026 to be $7,010,631, with the lowest XBIO revenue forecast at $6,735,705, and the highest XBIO revenue forecast at $7,216,826.
In 2027, XBIO is forecast to generate $5,842,193 in revenue, with the lowest revenue forecast at $5,613,087 and the highest revenue forecast at $6,014,022.